CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 548 enrolled
Drug / intervention
Lacosamide 50 mg +2 moredrug
Likely dose
Lacosamide 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01710657
NCT01710657Phase 3Completed

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Uncontrolled Partial-Onset Seizures With or Without Secondary Generalization

UCB Pharma SA·interventional·Posted Oct 19, 2012·Updated Aug 25, 2017

In Brief

A Phase 3 clinical trial evaluating Lacosamide 50 mg, Lacosamide 100 mg, and 1 other intervention for Epilepsy and Partial Onset Seizures. Completed, enrolled 548 participants across 76 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of 200 and 400 mg/day of orally administered Lacosamide as adjunctive therapy compared with placebo in Japanese and Chinese adults with uncontrolled Partial-Onset Seizures with or without secondary generalization.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina, Japan
CollaboratorsUCB Japan Co. Ltd.

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 19, 2012
Enrollment StartSep 1, 2012
Primary CompletionJul 1, 2014
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.7 years ago

Interventions

Lacosamide 50 mgdrug

* Active Substance: Lacosamide * Pharmaceutical Form: Film-coated tablet * Concentration: 50 mg * Route of Administration: Oral use

Lacosamide 100 mgdrug

* Active Substance: Lacosamide * Pharmaceutical Form: Film-coated tablet * Concentration: 100 mg * Route of Administration: Oral use

Placebodrug

Matching oral Placebo tablets twice daily for 16 weeks.